desentum
Espoo, FI · Founded 2011 · 14 employees on LinkedIn · 1 known investors
Desentum is a clinical-stage biopharmaceutical company developing allergen immunotherapy (AIT) products based on recombinant allergens modified to suppress histamine release during desensitization, aiming to reduce adverse effects and treatment time. Its lead programs target birch pollen, peanut, and cat allergies.
Investors · 1
Frequently asked questions
- What does desentum do?
- Desentum is a clinical-stage biopharmaceutical company developing allergen immunotherapy (AIT) products based on recombinant allergens modified to suppress histamine release during desensitization, aiming to reduce adverse effects and treatment time. Its lead programs target birch pollen, peanut, and cat allergies.
- Who are desentum's investors?
- desentum's investors include Voima Ventures.
- Where is desentum headquartered?
- desentum is headquartered in Espoo, FI.